CARDIOVASCULAR JOURNAL OF AFRICA • Vol 22, No 1, January/February 2011
44
AFRICA
ischaemic cardiomyopathies.
Eur Heart J
2005;
26
: 1461–1474.
54. Marcu CB, Nijveldt R, Beek AM, Van Rossum AC. Delayed contrast
enhancement magnetic resonance imaging for the assessment of cardiac
disease.
Heart Lung Circ
2007;
16
: 70–78.
55. Nagueh SF, Mahmarian JJ. Noninvasive cardiac imaging in patients with
hypertrophic cardiomyopathy.
J Am Coll Cardiol
2006;
48
: 2410–2422.
56. Sechtem U, Mahrholdt H, Vogelsberg H. Cardiac magnetic resonance in
myocardial disease.
Heart
2007;
93
: 1520–1527.
57. De Cobelli F, Esposito A, Belloni E,
et al
. Delayed-enhanced cardiac
MRI for differentiation of Fabry’s disease from symmetric hypertrophic
cardiomyopathy.
Am J Roentgenol
2009;
192
: W97–102.
58. Wu KC, Weiss RG, Thiemann DR,
et al
. Late gadolinium enhancement
by cardiovascular magnetic resonance heralds an adverse prognosis in
nonischemic cardiomyopathy.
J Am Coll Cardiol
2008;
51
: 2414–2421.
59. Imbriaco M, Spinelli L, Cuocolo A,
et al
. MRI characterization of
myocardial tissue in patients with Fabry’s disease.
Am J Roentgenol
2007;
188
: 850–853.
60. Sachdev B, Takenaka T, Teraguchi H,
et al
. Prevalence of Anderson-
Fabry disease in male patients with late onset hypertrophic cardiomyo-
pathy.
Circulation
2002;
105
: 1407–1411.
61. Chimenti C, Pieroni M, Morgante E,
et al
. Prevalence of Fabry
disease in female patients with late-onset hypertrophic cardiomyopathy.
Circulation
2004;
110
: 1047–1053.
62. Monserrat L, Gimeno-Blanes JR, Marín F,
et al
. Prevalence of Fabry
disease in a cohort of 508 unrelated patients with hypertrophic cardio-
myopathy.
J Am Coll Cardiol
2007;
50
: 2399–2403.
63. Eng CM, Guffon N, Wilcox WR,
et al
. Safety and efficacy of recom-
binant human alpha-galactosidase A--replacement therapy in Fabry’s
disease.
N Engl J Med
2001;
345
: 9–16.
64. Banikazemi M, Bultas J, Waldek S,
et al
. Agalsidase-beta therapy for
advanced Fabry disease: a randomized trial.
Ann Intern Med
2007;
146
:
77–86.
65. Schiffmann R, Kopp JB, Austin HA 3rd,
et al
. Enzyme replacement
therapy in Fabry disease: a randomized controlled trial.
J Am Med Assoc
2001;
285
: 2743–2749.
66. Spinelli L, Pisani A, Sabbatini M,
et al
. Enzyme replacement therapy
with agalsidase beta improves cardiac involvement in Fabry’s disease.
Clin Genet
2004;
66
: 158–165.
67. Beer M, Weidemann F, Breunig F,
et al
. Impact of enzyme replacement
therapy on cardiac morphology and function and late enhancement in
Fabry’s cardiomyopathy.
Am J Cardiol
2006;
97
: 1515–1518.
68. Hughes DA, Elliott PM, Shah J,
et al
. Effects of enzyme replace-
ment therapy on the cardiomyopathy of Anderson-Fabry disease: a
randomised, double-blind, placebo-controlled clinical trial of agalsidase
alfa.
Heart
2008;
94
: 153–158.
69. Kovacevic-Preradovic T, Zuber M, Jost CH,
et al
. Anderson-Fabry
disease: long-term echocardiographic follow-up under enzyme replace-
ment therapy.
Eur J Echocardiogr
2008;
9
: 729–735.
70. Koskenvuo JW, Hartiala JJ, Nuutila P,
et al
. Twenty-four-month alpha-
galactosidase A replacement therapy in Fabry disease has only minimal
effects on symptoms and cardiovascular parameters.
J Inherit Metab Dis
2008;
31
: 432–441.
71. Weidemann F, Niemann M, Breunig F,
et al
. Long-term effects of
enzyme replacement therapy on Fabry cardiomyopathy: evidence for a
better outcome with early treatment.
Circulation
2009;
119
: 524–529.
72. Waldek S. PR interval and the response to enzyme-replacement therapy
for Fabry’s disease.
N Engl J Med
2003;
348
: 1186–1187.
73. Chimenti C, Morgante E, Tanzilli G,
et al
. Angina in Fabry disease
reflects coronary small vessel disease.
Circ Heart Fail
2008;
1
: 161–169.
74. Elliott PM, Kindler H, Shah JS,
et al
. Coronary microvascular dysfunc-
tion in male patients with Anderson-Fabry disease and the effect of treat-
ment with alpha galactosidase A.
Heart
2006;
92
: 357–360.
75. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. 2009
Appropriateness criteria for coronary revascularization.
J Am Coll
Cardiol
2009;
53:
530–553.
76. Chimenti C, Morgante E, Critelli G, Russo MA, Frustaci A. Coronary
artery bypass grafting for Fabry’s disease: veins more suitable than arter-
ies?
Hum Pathol
2007;
38
: 1864–1867.
77. Bonow RO, Carabello BA, Chatterjee K,
et al
. 2008 focused update
incorporated into the ACC/AHA 2006 guidelines for the management
of patients with valvular heart disease.
J Am Coll Cardiol
2008;
52
(13):
e1–142.
78. Choi S, Seo H, Park M,
et al
. Fabry disease with aortic regurgitation.
Ann Thorac Surg
2009;
87
: 625–628.
79. Miyata M, Sato T, Iwai-Takano M, Suzuki H, Ishibashi T, Takeishi Y.
Mitral valve replacement due to mitral valve regurgitation in patient with
Fabry disease.
J Card Fail
2008;
14
: S151.
80. Epstein AE, DiMarco JP, Ellenbogen KA,
et al
. 2008 Guidelines for
device-based therapy of cardiac rhythm abnormalities.
J Am Coll
Cardiol
2008;
51
: e1–62.
81. Hunt SA, Abraham WT, Chin MH,
et al
. 2009 Focused update incorpo-
rated into the ACC/AHA 2005 Guidelines for the diagnosis and manage-
ment of heart failure in adults.
J Am Coll Cardiol
2009;
53
: e1–e90.
82. Fukuta H, Little WC. Observational studies of statins in heart failure
with preserved systolic function.
Heart Fail Clin
2008;
4
: 209–216.
83. Magage S, Linhart A, Bultas J,
et al
. Fabry disease: percutaneous trans-
luminal septal myocardial ablation markedly improved symptomatic left
ventricular hypertrophy and outflow tract obstruction in a classically
affected male.
Echocardiography
2005;
22
: 333–339.
84. Karras A, De Lentdecker P, Delahousse M,
et al
. Combined heart and
kidney transplantation in a patient with Fabry disease in the enzyme
replacement therapy era.
Am J Transplant
2008;
8
: 1345–1348.
